血漿誘導体市場：製品タイプ、用途、エンドユーザー、供給源別-2025-2030年世界予測

血漿誘導体市場は、2023年に4億8,324万米ドルと評価され、2024年には5億2,383万米ドルに達すると予測され、CAGR 9.65%で成長し、2030年には9億2,133万米ドルに達すると予測されています。

血漿誘導体は、免疫グロブリン、凝固因子、アルブミンなど、ヒト血漿を起源とする治療製品を指し、様々な病状の治療に使用されます。これらの誘導体の必要性は、免疫不全障害、血友病、自己免疫疾患などの治療における重要な役割に由来します。最終用途の範囲には、主に病院、診療所、研究機関が含まれ、そこではこのような治療薬が救命介入に不可欠です。同市場は、血漿分画の技術的進歩、ヘルスケア・インフラを改善するための政府の取り組み、研究機関と製薬会社の協力関係の増加といった要因によって大きな影響を受けています。人口の高齢化と慢性疾患の罹患率の増加は、市場の成長をさらに加速させる。しかし、厳しい規制政策と生産コストの高さが顕著な課題となっています。さらに、血漿提供プロセスに関する倫理的懸念や輸血感染症の潜在的リスクが市場拡大の妨げとなっています。とはいえ、遺伝子研究とバイオテクノロジーの進歩は、より効率的な組み換え血漿由来製品の開発機会を提供しています。血漿採取プロセスの改善とサプライチェーンの効率化に注力することで、いくつかの制約を緩和することができます。合成生物学における技術革新は、より持続可能で倫理的な生産手法への道を開き、ヒトドナーへの依存を減らす可能性があります。このような分野を開拓するために研究開発パートナーシップに投資し、合理的でコンプライアンスに準拠した生産を確保し、ヘルスケア支出の急増を目の当たりにしている新興市場への地理的なリーチを拡大することによって、事業の成長を達成することができます。さらに、血漿由来製品の利点に関する患者やヘルスケア提供者の教育を強化することで、市場の受容と利用が促進される可能性があります。全体として、潜在的な技術革新がより低コストで倫理的に健全な代替品への道を開くことで、市場は成長の態勢を整えています。

市場力学：急速に進化する血漿誘導体市場の主要市場インサイトを公開

血漿誘導体市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の蔓延が世界的に血漿誘導体需要を牽引
  • ヘルスケアインフラと先進血漿採取技術への投資の増加
  • 血漿誘導体の研究開発を支援する政府のイニシアチブと有利な政策
  • 患者および医療従事者の血漿由来治療に対する認識とアクセシビリティの向上
• 市場抑制要因
  • 誘導体製造のための血漿の収集、保管、流通におけるロジスティクスの複雑さ
  • 血漿誘導体のサプライチェーンに影響を及ぼす倫理的懸念とドナー募集の課題
• 市場機会
  • 腫瘍学およびクリティカルケアにおける血漿由来療法の使用拡大
  • 血漿誘導体の生産効率を向上させる技術の進歩
  • 公衆衛生上の緊急事態における血漿製剤の使用を促進する政府の取り組み
• 市場の課題
  • 血漿の採取と処理にかかるコストの高さが市場拡大を制限
  • 血漿誘導体市場における代替療法やバイオテクノロジー技術革新との競合激化

ポーターの5つの力：血漿誘導体市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血漿誘導体市場における外部からの影響の把握

外部マクロ環境要因は、血漿誘導体市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血漿誘導体市場における競合情勢の把握

血漿誘導体市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血漿誘導体市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血漿誘導体市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血漿誘導体市場における成功への道筋を描く

血漿誘導体市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加により、血漿誘導体の需要が世界的に高まっています
    • ヘルスケアインフラと高度な血漿採取技術への投資増加
    • 血漿分画製剤の研究開発を支援する政府の取り組みと有利な政策
    • 患者とヘルスケア従事者の間で血漿由来療法の認知度と利用しやすさが高まっている
  • 抑制要因
    • 誘導体製造のための血漿の収集、保管、配送における物流の複雑さ
    • 血漿誘導体のサプライチェーンに影響を与える倫理的懸念と寄付者募集の課題
  • 機会
    • 腫瘍学および集中治療における血漿由来療法の利用拡大
    • 血漿分画製剤の生産効率を向上させる技術の進歩
    • 公衆衛生上の緊急事態における血漿製品の使用を促進する政府の取り組み
  • 課題
    • 血漿の採取と処理にかかるコストの高さが市場拡大を制限している
    • 血漿分画製剤市場における代替療法とバイオテクノロジーの革新による競合の激化
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血漿誘導体市場：製品タイプ別

• アルブミン
• 凝固因子
  • 第IX因子
  • 第VIII因子
  • フィブリノゲン濃縮物
  • プロトロンビン複合体濃縮物（PCC）
• 免疫グロブリン
  • 静脈内（IVIG）
  • 皮下（SCIG）

第7章 血漿誘導体市場：用途別

• 診断
• 調査
• 治療目的の使用
  • 心臓病学
  • 血液腫瘍学
  • 免疫学
  • 感染症
  • 神経学
  • 呼吸器科
  • 外傷緊急事態

第8章 血漿誘導体市場：エンドユーザー別

• 学術調査機関
• 血液銀行
• クリニック
• 診断検査室
• 病院

第9章 血漿誘導体市場：ソース別

• ヒト血漿
• 非ヒト血漿

第10章 南北アメリカの血漿誘導体市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の血漿誘導体市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの血漿誘導体市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. ADMA Biologics
• 2. ARTHREX GmbH
• 3. Bio Products Laboratory Ltd
• 4. Biotest AG
• 5. BPL Holdings
• 6. China Biologic Products Holdings, Inc.
• 7. CSL Behring
• 8. Emergent BioSolutions
• 9. Grifols
• 10. Intas Pharmaceuticals
• 11. Kamada Ltd.
• 12. Kedrion Biopharma
• 13. LFB Group
• 14. Octapharma
• 15. Prothya Biosolutions
• 16. RAAS Blood Products
• 17. Sanquin
• 18. Shanghai RAAS Blood Products Co., Ltd.
• 19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
• FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BLOOD PLASMA DERIVATIVES MARKET DYNAMICS
• TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRINOGEN CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE (PCC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS (IVIG), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS (SCIG), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TRAUMA EMERGENCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NON-HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 62. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 65. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 67. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 99. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 101. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 102. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 104. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 106. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 108. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 109. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 111. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 118. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 125. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 132. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 139. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 146. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 153. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 160. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 167. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 174. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 189. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 196. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 203. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 210. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 217. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 224. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 226. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 228. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 229. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 231. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 238. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 244. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 245. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 246. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 251. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 252. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 253. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 254. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 255. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 256. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 257. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 258. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 259. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 261. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 262. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 263. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 264. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 266. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 267. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 273. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 279. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 280. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 281. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 286. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 287. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 293. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 294. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 295. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 300. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 301. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 302. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 307. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 308. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 309. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 314. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 315. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 316. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 321. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
• TABLE 322. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 323. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 328. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)

TABLE 3

The Blood Plasma Derivatives Market was valued at USD 483.24 million in 2023, expected to reach USD 523.83 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 921.33 million by 2030.

Blood plasma derivatives refer to therapeutic products originating from human plasma, including immunoglobulins, clotting factors, albumin, and others, used to treat a variety of medical conditions. The necessity of these derivatives stems from their vital role in treating immunodeficiency disorders, hemophilia, and autoimmune diseases, among others, which are on the rise globally due to increased diagnosis and awareness. The end-use scope primarily encompasses hospitals, clinics, and research institutions, where such therapeutics are crucial for life-saving interventions. The market is significantly influenced by factors like technological advancements in plasma fractionation, government initiatives to improve healthcare infrastructure, and increased collaborations between research institutions and pharmaceutical companies. An aging population and higher prevalences of chronic diseases further amplify market growth. However, stringent regulatory policies and the high cost of production pose notable challenges. Furthermore, ethical concerns related to plasma donation processes and potential risks of transfusion-transmitted infections hinder market expansion. Nevertheless, advancements in genetic research and biotechnology present opportunities for development of more efficient and recombinant plasma-derived products. Focusing on improving plasma collection processes and enhancing supply chain efficiency can mitigate some limitations. Innovations in synthetic biology open channels for more sustainable and ethical production methodologies, possibly reducing dependence on human donors. Business growth can be achieved by investing in R&D partnerships to explore these areas, ensuring streamlined and compliant production, and by expanding geographical reach to emerging markets witnessing an upsurge in healthcare spending. Additionally, enhancing patient and healthcare provider education on the benefits of plasma-derived products could foster market acceptance and usage. Overall, the market is poised for growth with potential innovations paving the way for less costly and ethically sound alternatives.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
  • Rising investments in healthcare infrastructure and advanced plasma collection technologies
  • Government initiatives and favorable policies supporting blood plasma derivative research and development
  • Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
• Market Restraints
  • Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
  • Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
• Market Opportunities
  • Expanding use of plasma-derived therapies in oncology and critical care
  • Technological advancements improving production efficiency of plasma derivatives
  • Government initiatives promoting the use of plasma products in public health emergencies
• Market Challenges
  • High cost of blood plasma collection and processing limiting market expansion
  • Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market

Porter's Five Forces: A Strategic Tool for Navigating the Blood Plasma Derivatives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Plasma Derivatives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Plasma Derivatives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Plasma Derivatives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Plasma Derivatives Market

A detailed market share analysis in the Blood Plasma Derivatives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Plasma Derivatives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Plasma Derivatives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Plasma Derivatives Market

A strategic analysis of the Blood Plasma Derivatives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Plasma Derivatives Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, ARTHREX GmbH, Bio Products Laboratory Ltd, Biotest AG, BPL Holdings, China Biologic Products Holdings, Inc., CSL Behring, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Kamada Ltd., Kedrion Biopharma, LFB Group, Octapharma, Prothya Biosolutions, RAAS Blood Products, Sanquin, Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Albumin, Coagulation Factors, and Immunoglobulins. The Coagulation Factors is further studied across Factor IX, Factor VIII, Fibrinogen Concentrate, and Prothrombin Complex Concentrate (PCC). The Immunoglobulins is further studied across Intravenous (IVIG) and Subcutaneous (SCIG).
• Based on Application, market is studied across Diagnostics, Research, and Therapeutic Use. The Therapeutic Use is further studied across Cardiology, Hemato-oncology, Immunology, Infectious Diseases, Neurology, Pulmonology, and Trauma Emergencies.
• Based on End User, market is studied across Academic & Research Institutes, Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals.
• Based on Source, market is studied across Human Plasma and Non-Human Plasma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
    • 5.1.1.2. Rising investments in healthcare infrastructure and advanced plasma collection technologies
    • 5.1.1.3. Government initiatives and favorable policies supporting blood plasma derivative research and development
    • 5.1.1.4. Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
  • 5.1.2. Restraints
    • 5.1.2.1. Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
    • 5.1.2.2. Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding use of plasma-derived therapies in oncology and critical care
    • 5.1.3.2. Technological advancements improving production efficiency of plasma derivatives
    • 5.1.3.3. Government initiatives promoting the use of plasma products in public health emergencies
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of blood plasma collection and processing limiting market expansion
    • 5.1.4.2. Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Blood Plasma Derivatives Market, by Product Type

• 6.1. Introduction
• 6.2. Albumin
• 6.3. Coagulation Factors
  • 6.3.1. Factor IX
  • 6.3.2. Factor VIII
  • 6.3.3. Fibrinogen Concentrate
  • 6.3.4. Prothrombin Complex Concentrate (PCC)
• 6.4. Immunoglobulins
  • 6.4.1. Intravenous (IVIG)
  • 6.4.2. Subcutaneous (SCIG)

7. Blood Plasma Derivatives Market, by Application

• 7.1. Introduction
• 7.2. Diagnostics
• 7.3. Research
• 7.4. Therapeutic Use
  • 7.4.1. Cardiology
  • 7.4.2. Hemato-oncology
  • 7.4.3. Immunology
  • 7.4.4. Infectious Diseases
  • 7.4.5. Neurology
  • 7.4.6. Pulmonology
  • 7.4.7. Trauma Emergencies

8. Blood Plasma Derivatives Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Blood Banks
• 8.4. Clinics
• 8.5. Diagnostic Laboratories
• 8.6. Hospitals

9. Blood Plasma Derivatives Market, by Source

• 9.1. Introduction
• 9.2. Human Plasma
• 9.3. Non-Human Plasma

10. Americas Blood Plasma Derivatives Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Blood Plasma Derivatives Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Blood Plasma Derivatives Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ADMA Biologics
• 2. ARTHREX GmbH
• 3. Bio Products Laboratory Ltd
• 4. Biotest AG
• 5. BPL Holdings
• 6. China Biologic Products Holdings, Inc.
• 7. CSL Behring
• 8. Emergent BioSolutions
• 9. Grifols
• 10. Intas Pharmaceuticals
• 11. Kamada Ltd.
• 12. Kedrion Biopharma
• 13. LFB Group
• 14. Octapharma
• 15. Prothya Biosolutions
• 16. RAAS Blood Products
• 17. Sanquin
• 18. Shanghai RAAS Blood Products Co., Ltd.
• 19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• 20. Takeda Pharmaceutical Company Limited